Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
We studied the effect of intravenous infusion of synthetic truncated GLP-1 (proglucagon 78-107-amide) on fasting and postprandial gastric acid secretion, gastric emptying, and pancreatic secretion of trypsin and lipase in eight normal volunteers using marker dilution and aspiration technique. The infusion resulted in a plasma concentration of 110 +/- 14 pmol/liter (mean +/- SEM). Truncated GLP-1 significantly inhibited postprandial acid secretion by 43 +/- 11% in spite of unchanged plasma gastrin concentration. Gastric emptying rate decreased significantly; 50% emptying time increased from 16 +/- 2 min to 30 +/- 5 min. Postprandial trypsin and lipase outputs were significantly inhibited by 47 +/- 17% and 40 +/- 9% during truncated GLP-1 infusion. Pancreatic enzyme output was linearly correlated to gastric emptying, and truncated GLP-1 did not affect this relationship, suggesting that the effect on pancreatic secretion was secondary to the effect on gastric emptying. Postprandial insulin and glucagon concentrations were similar with and without truncated GLP-1 infusion in spite of significantly lower blood glucose levels (5.2 +/- 0.2 versus 3.7 +/- 0.3), indicating that GLP-1 stimulated insulin secretion and inhibited glucagon secretion. In conclusion, our results suggest that truncated GLP-1 act as a physiological inhibitor of gastric and pancreatic functions in man.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In particular, GLP-1R agonism not only emerged as a powerful tool in the treatment of T2D and excess adiposity56, but also displayed favorable effects on the cardiovascular system57 and neurodegenerative diseases55.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [57]
In the citing paper
“GLP-1 has been shown to inhibit glucagon secretion and slow gastric emptying.5, 6”
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Physiology of the Gastrointestinal Tract
Ouyang, A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410100162049 · Cited by 950
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationMojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Albano, J. D. M., Ekins, R. P., Maritz, G., & Turner, R. C. (1972) · Acta Endocrinologica · doi:10.1530/acta.0.0700487 · Cited by 620
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Self-citationØRSKOV, C., HOLST, J. J., KNUHTSEN, S., BALDISSERA, F. G. A., POULSEN, S. S., & NIELSEN, O. V. (1986) · Endocrinology · doi:10.1210/endo-119-4-1467 · Cited by 482
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citation
Research works printed but not linked: 4
- Holst JJ: Enteroglucagon. Adv Metab Dis 11:392?419, 1988
- Dimagno EP: Alternations and consequences of interdigestive and poststimulatory human exocrine pancreatic secretion in health and disease. Scand J Gastroenterol 12(suppl 87): 69, 1983
- Holst JJ, Creutzfeldt M, Holm G, Jensen E, Poulsen D, Sparsø B, Schmidt A: Persistent glucagonemia after pancreatectomy in pigs. Diabete Metab 4:75?79, 1978
- Solomon TE: Control of exocrine pancreatic secretion.In Physiology of the Gastrointestinal Tract, 2nd ed. LR Johnson (ed). New York, Raven Press, 1987, pp 1173?1208
Cited by
Items 201–300 of 687
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Ishikawa, Y., Hira, T., Inoue, D., Harada, Y., Hashimoto, H., Fujii, M., Kadowaki, M., & Hara, H. (2015) · Food & Function · doi:10.1039/c4fo01054j · Cited by 80
Baggio, L. (2000) · Endocrinology · doi:10.1210/en.141.10.3703 · Cited by 79
Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 82
Delgado‐Aros, S., Vella, A., Camilleri, M., Low, P. A., Burton, D. D., Thomforde, G. M., & Stephens, D. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00422.x · Cited by 77
Incretins and other peptides in the treatment of diabetes
Todd, J. F., & Bloom, S. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02071.x · Cited by 76
Actions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 73
Self-citationOgbourne, S. M., & Parsons, P. G. (2014) · Fitoterapia · doi:10.1016/j.fitote.2014.07.002 · Cited by 80
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
Rosenstock, J., & Zinman, B. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280a02f65 · Cited by 78
Glucagonlike Peptide-1 (GLP-1) Participation in Ileal Brake Induced by Intraluminal Peptones in Rat
Giralt, M., & Vergara, P. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026654417697 · Cited by 82
Ørskov, J. J. H. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/clb.61.234.75.85 · Cited by 71
Self-citationThe effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum
Hansen, L., & Holst, J. J. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00157-x · Cited by 81
Self-citationTsai, T., Yeh, T., Chen, X., Hsu, T., Jao, Y., Huang, C., Song, J., Huang, Y., Chien, C., Chiu, J.-H., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1002556 · Cited by 74
Incretin Mimetics as Emerging Treatments for Type 2 Diabetes
Joy, S. V., Rodgers, P. T., & Scates, A. C. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e245 · Cited by 71
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Effects of the GLP‐1 Agonist Exendin‐4 on Intravenous Ethanol Self‐Administration in Mice
Sørensen, G., Caine, S. B., & Thomsen, M. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13199 · Cited by 69
Gutniak, M. K., Juntti-Berggren, L., Hellström, P. M., Guenifi, A., Holst, J. J., & Efendic, S. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.857 · Cited by 70
Self-citationInteractions between gastric emptying and satiety, with special reference to glucagon-like peptide-1
Hellström, P. M., & Näslund, E. B. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00618-7 · Cited by 78
Wettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · Peptides · doi:10.1016/s0196-9781(98)00020-5 · Cited by 67
Self-citationLiu, H., Hu, Y., Simpson, R. W., & Dear, A. E. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0387 · Cited by 67
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative
Agersø, H., & Vicini, P. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00073-3 · Cited by 70
Glycaemic effects of incretins in Type 1 diabetes mellitus
Dupre, J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.003 · Cited by 72
Cai, X., Ji, L., Chen, Y., Yang, W., Zhou, L., Han, X., Zhang, S., & Ji, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12625 · Cited by 66
Wettergren, A., Pridal, L., Wøjdemann, M., & Holst, J. J. (1998) · Regulatory Peptides · doi:10.1016/s0167-0115(98)00044-5 · Cited by 76
Self-citationMedium-Dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1
Andersen, N. H., Brodsky, Y., Neidigh, J. W., & Prickett, K. S. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00263-2 · Cited by 71
Schirra, J., Leicht, P., Hildebrand, P., Beglinger, C., Arnold, R., Goke, B., & Katschinski, M. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1560177 · Cited by 65
Wettergren, A., Maina, P., Boesby, S., & Holst, J. J. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709025098 · Cited by 65
Self-citationGive the Receptor a Brake: Slowing Gastric Emptying by GLP-1
Tong, J., & D’Alessio, D. (2014) · Diabetes · doi:10.2337/db13-1764 · Cited by 63
Raben, A., Holst, J. J., Madsen, J., & Astrup, A. V. (2001) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.177 · Cited by 66
Self-citationBode, B. W., Brett, J., Falahati, A., & Pratley, R. E. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.09.007 · Cited by 71
Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms
Zhang, J., & Ritter, R. C. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00114.2011 · Cited by 62
Farr, S., Baker, C., Naples, M., Taher, J., Iqbal, J., Hussain, M., & Adeli, K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304873 · Cited by 61
Kim, D., Kowalchick, J. E., Brockunier, L. L., Parmee, E. R., Eiermann, G. J., Fisher, M. H., He, H., Leiting, B., Lyons, K. A., Scapin, G., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070330v · Cited by 68
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
Pei, Z., Li, X., Longenecker, K. L., von Geldern, T. W., Wiedeman, P. E., Lubben, T. H., Zinker, B. A., Stewart, K. D., Ballaron, S. J., Stashko, M. A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051283e · Cited by 67
Palladino, A. A., Sayed, S., Levitt Katz, L. E., Gallagher, P. R., & De León, D. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1263 · Cited by 61
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
López de Maturana, R., & Donnelly, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03492-0 · Cited by 60
Dipeptidyl peptidase iv inhibitors and diabetes therapy
McIntosh, C. H. S. (2007) · Frontiers in bioscience · doi:10.2741/2797 · Cited by 62
Rayner, C. K., Park, H. S., Wishart, J. M., Kong, M.-F., Doran, S. M., & Horowitz, M. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.2.r360 · Cited by 59
Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Sumida, Y., Seko, Y., Yoneda, M., & Japan Study Group of NAFLD (JSG‐NAFLD) (2016) · Hepatology Research · doi:10.1111/hepr.12856 · Cited by 60
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
“[70] Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J,”
BackgroundChronic diarrhoea following surgery for colon cancer—frequency, causes and treatment options
Yde, J., Larsen, H. M., Laurberg, S., Krogh, K., & Moeller, H. B. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-2993-y · Cited by 64
Kim, D., Kowalchick, J. E., Edmondson, S. D., Mastracchio, A., Xu, J., Eiermann, G. J., Leiting, B., Wu, J. K., Pryor, K. D., Patel, R. A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.098 · Cited by 58
Meier, J. J., Gallwitz, B., & Nauck, M. A. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00002 · Cited by 67
Hücking, K., Kostic, Z., Pox, C., Ritzel, R., Holst, J. J., Schmiegel, W., & Nauck, M. A. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01451.x · Cited by 57
Self-citationMetabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
Nakamaru, Y., Hayashi, Y., Ikegawa, R., Kinoshita, S., Madera, B. P., Dave, G., Kawaguchi, A., Davies, M., Mair, S. J., Yamazaki, H., et al. (2013) · Xenobiotica · doi:10.3109/00498254.2013.816891 · Cited by 55
Li, L., Miao, Z., Liu, R., Yang, M., Liu, H., & Yang, G. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00051 · Cited by 55
Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats
Simonsen, L., Pilgaard, S., Orskov, C., Rosenkilde, M. M., Hartmann, B., Holst, J. J., & Deacon, C. F. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00453.2006 · Cited by 54
Self-citationAndersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Self-citationComplications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 65
The role of the Wnt signaling pathway in incretin hormone production and function
Chiang, Y., Ip, W., & Jin, T. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00273 · Cited by 63
Gut hormones as pharmaceuticals
Holst, J. J. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00185-3 · Cited by 65
Self-citationAlcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1
Jerlhag, E. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146562 · Cited by 53
“glucose-dependent insulin secretion, inhibits the glucagon secretion and reduces the gastric motility (Gutniak et al., 1992; Holst and Seino, 2009; Hvidberg et al., 1994; Matsuyama et al., 1988; Orskov et al., 1988; Wettergren et al., 1993).”
GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat
Bozkurt, A., Näslund, E. B., Holst, J. J., & Hellström, P. M. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00095-2 · Cited by 59
Self-citationTODD, J. F., EDWARDS, C. M. B., GHATEI, M. A., MATHER, H. M., & BLOOM, S. R. (1998) · Clinical Science · doi:10.1042/cs0950325 · Cited by 53
Satoh, F. (2000) · Endocrinology · doi:10.1210/en.141.4.1301 · Cited by 53
Neumiller, J. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.013 · Cited by 59
Incretins, diabetes, and bariatric surgery: a review
Fetner, R., McGinty, J., Russell, C. D., Pi-Sunyer, X., & Laferrère, B. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.09.001 · Cited by 57
Yasuda, N., Nagakura, T., Yamazaki, K., Inoue, T., & Tanaka, I. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)01637-5 · Cited by 56
Vollmer, K., Gardiwal, H., Menge, B. A., Goetze, O., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2197 · Cited by 51
Self-citationTaspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency
Sebokova, E., Christ, A. D., Wang, H., Sewing, S., Dong, J. Z., Taylor, J., Cawthorne, M. A., & Culler, M. D. (2010) · Endocrinology · doi:10.1210/en.2009-1459 · Cited by 51
Deshpande, M. C., Venkateswarlu, V., Babu, R. K., & Trivedi, R. K. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.024 · Cited by 58
Glucagon-like Peptide-1 (GLP-1) and the Control of Glucose Metabolism in Mammals and Teleost Fish
Mojsov, S. (2000) · American Zoologist · doi:10.1668/0003-1569(2000)040[0246:glpgat]2.0.co;2 · Cited by 57
Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies
Meece, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167336 · Cited by 50
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Piccini, S., Favacchio, G., Panico, C., Morenghi, E., Folli, F., Mazziotti, G., Lania, A. G., & Mirani, M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01800-z · Cited by 49
No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man
Long, S. J., Sutton, J. A., Amaee, W. B., Giouvanoudi, A., Spyrou, N. M., Rogers, P. J., & Morgan, L. M. (1999) · British Journal of Nutrition · doi:10.1017/s0007114599000513 · Cited by 49
HOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 70
Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle
Amato, A., Baldassano, S., Liotta, R., Serio, R., & Mulè, F. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0525 · Cited by 48
Retlich, S., Duval, V., Graefe‐Mody, U., Jaehde, U., & Staab, A. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009356444 · Cited by 50
Hou, Y., Ernst, S. A., Heidenreich, K., & Williams, J. A. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00293.2015 · Cited by 47
Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats
Gülpinar, M. A., Bozkurt, A., Coşkun, T., Ulusoy, N. B., & Yeǧen, B. Ç. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.6.g924 · Cited by 48
RANGANATH, L., NORRIS, F., MORGAN, L., WRIGHT, J., & MARKS, V. (1999) · Clinical Science · doi:10.1042/cs0960335 · Cited by 47
Steinert, R. E., Poller, B., Castelli, M. C., Friedman, K., Huber, A. R., Drewe, J., & Beglinger, C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.159 · Cited by 47
Physiological parameters governing the action of pancreatic lipase
Brownlee, I. A., Forster, D. J., Wilcox, M. D., Dettmar, P. W., Seal, C. J., & Pearson, J. P. (2010) · Nutrition Research Reviews · doi:10.1017/s0954422410000028 · Cited by 61
Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment.
Higgins, V., & Adeli, K. (2017) · PubMed Central · Cited by 58
Baraboi, E.-D., Smith, P., Ferguson, A. V., & Richard, D. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00326.2009 · Cited by 46
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
Benito, E., Blázquez, E., & Bosch, M. A. (1998) · Endocrinology · doi:10.1210/en.139.5.2363 · Cited by 45
Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44
Banno, Y., Miyamoto, Y., Sasaki, M., Oi, S., Asakawa, T., Kataoka, O., Takeuchi, K., Suzuki, N., Ikedo, K., Kosaka, T., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.059 · Cited by 44
Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
Neumiller, J. J., & Campbell, R. K. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090555 · Cited by 42
Zueco, J. A., Esquifino, A. I., Chowen, J. A., Alvarez, E., Castrillón, P. O., & Blázquez, E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720010.x · Cited by 44
Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes
Parsons, G. B., Souza, D. W., Wu, H., Yu, D., Wadsworth, S. G., Gregory, R. J., & Armentano, D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302842 · Cited by 45
Kadowaki, T., & Kondo, K. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12092 · Cited by 44
Liu, M.-J., Shin, S., Li, N., Shigihara, T., Lee, Y.-S., Yoon, J., & Jun, H. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300005 · Cited by 44
Koole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 42
Picha, K. M., Cunningham, M. R., Drucker, D. J., Mathur, A. S., Ort, T., Scully, M. S., Soderman, A. R., Spinka-Doms, T., Stojanovic-Susulic, V., Thomas, B. A., et al. (2008) · Diabetes · doi:10.2337/db07-1775 · Cited by 41
Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs
Nagell, C. F., Wettergren, A., Ørskov, C., & Holst, J. J. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520500408253 · Cited by 42
Self-citationKong, M., King, P., Macdonald, I. A., Blackshaw, P. E., Horowitz, M., Perkins, A. C., Armstrong, E., Buchanan, K. D., & Tattersall, R. B. (1999) · Diabetologia · doi:10.1007/s001250051164 · Cited by 40
Al-Sabah, S., & Donnelly, D. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01043-3 · Cited by 41
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
Fortin, S. M., Chartoff, E. H., & Roitman, M. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.220 · Cited by 45
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Ji, X., Su, M., Wang, J., Deng, G., Deng, S., Li, Z., Tang, C., Li, J., Li, J., Zhao, L., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.021 · Cited by 43
Quast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14477 · Cited by 39
Luttikhold, J., de Ruijter, F. M., van Norren, K., Diamant, M., Witkamp, R. F., van Leeuwen, P. A. M., & Vermeulen, M. A. R. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12421 · Cited by 44
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Metadata
- Authors
- Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Digestive Diseases and Sciences
- Published
- 1993-04
- Volume
- 38
- Issue
- 4
- Pages
- 665-673
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2087063469
- Cited by
- 670
- References
- 39
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 20 · 2023: 9 · 2022: 14 · 2021: 22 · 2020: 10 · 2019: 19 · 2018: 17 · 2017: 18 · 2016: 23 · 2015: 27 · 2014: 25 · 2013: 21 · 2012: 25
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- gastric acid secretion, gastric emptying, postprandial insulin secretion, glucagon secretion, blood glucose, gastrin, incretins
- MeSH terms
- Adult, Depression, Chemical, Female, Gastric Acid, Gastric Emptying, Gastric Mucosa, Glucagon, Humans, Infusions, Intravenous, Lipase, Male, Pancreas, Peptide Fragments, Protein Precursors, Random Allocation, Reference Values, Time Factors, Trypsin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.